Management of Severe Hypertriglyceridemia

Introduction to Management

The American College of Cardiology recommends addressing medication noncompliance before adding additional agents, as noncompliance is a critical factor in treatment failure, especially in patients already on maximum-dose statins and ezetimibe 1.
The European Heart Journal suggests that achieving lipid targets is essential for reducing cardiovascular morbidity and mortality in high-risk patients, such as those with diabetes, hypertension, and aneurysms 2.

The European Heart Journal and Diabetes Care recommend that LDL-C should be below 55 mg/dL or 70 mg/dL for very high-risk patients, and the patient's current LDL-C of 138 mg/dL is above this goal 2, 3.
The American Diabetes Association recommends targeting HbA1c below 7% for diabetic patients, and optimizing glycemic control is crucial for managing hypertriglyceridemia in diabetic patients 3.

The American Heart Association recommends lifestyle interventions, including weight loss, eliminating added sugars, restricting saturated fat, increasing soluble fiber, and exercising at least 150 minutes per week, to reduce triglycerides by 20-70% 1.
The European Heart Journal suggests that a diet restricting saturated fat to less than 7% of total calories and increasing soluble fiber to more than 10 g/day can help reduce triglycerides 2.

The American College of Cardiology recommends adding fenofibrate for triglyceride management in high-risk patients with triglycerides approaching 500 mg/dL, as it provides a 30-50% triglyceride reduction 1.
The European Heart Journal suggests that icosapent ethyl can reduce major adverse cardiovascular events by 25% and provide an additional 20-50% triglyceride reduction when added to statin therapy 2.

The European Heart Journal recommends controlling blood pressure to a target systolic blood pressure of 130 mmHg and diastolic blood pressure below 80 mmHg, using a RAAS blocker as first-line therapy for diabetic patients with hypertension 2.

The American College of Cardiology recommends monitoring lipid panels, liver function tests, and creatine kinase levels regularly in patients on combination therapy, including statins, ezetimibe, and fenofibrate 4, 1.